Okyo announces FDA authorized single-patient expanded IND for urcosimod

OKYO Pharma (OKYO) announced that the U.S. Food and Drug Administration, FDA, has authorized a single-patient expanded access Investigational New Drug, IND, application submitted by Pedram Hamrah, MD, at the University of South Florida, for the use of urcosimod in a patient with neuropathic corneal pain. Under the FDA-authorized expanded access, urcosimod is being provided by OKYO Pharma for use in a patient with severe neuropathic corneal pain who has limited therapeutic options and no FDA-approved treatments available.